YD0743
Phase 2Small molecule
YD0743 is one of 36 small molecule programs targeting Sepsis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
100 competitors in Sepsis
#DrugCompanyPhaseTrials
1Dobutrex
PfizerPhase 2
Proamatine
TakedaPhase 2
Gleevec
NovartisPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sepsis1 trial
Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07413094·309 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YD0743. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details